ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2024
Sarcoidosis in north African people: about 35 cases.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimSarcoidosis is a systemic disease of unknown cause characterized by the formation of non-caseating granulomatous inflammation in various organs, mainly lungs and intrathoracic lymph nodes. Its clinical and paraclinical presentation can vary from mild to life-threatening. Our objective is to study the clinical, paraclinical and evolution profile of mediastino-pulmonary sarcoidosis.
methodsThis is a retrospective, descriptive and analytic study conducted over a 20-year period (January 2002 to December 2022). It compiled records of patients who were followed up for confirmed mediastino-pulmonary sarcoidosis.
resultsThe study included 35 patients with a mean age of 56.69 ± 14.42 . There was a clear predominance of female patients, with a male-to-female sex ratio of 0.346. The most common functional respiratory signs were dyspnea (82.9%) and dry cough (80%). Extra-respiratory symptoms were noted in 45.7% of cases, with the most common being polyarthralgia (28.6%), xerophthalmia (20%) and xerostomia (14.3%). The most common parenchymal lesions were micronodules (71.4%), nodules (51.4%), and peribronchovascular thickening (40%). The The right upper lobe (77.1%) and middle lobe (74.3%) were the most affected lobes. Hilar adenopathy (71.4%), paratracheal adenopathy (60%), and the aorto-pulmonary window (54.3%) were the most frequent lymph node involvements. Respiratory function tests revealed a restrictive ventilatory defect in 32% of cases and an obstructive ventilatory defect in 13% .Oral corticosteroids were initially administered in 60% of cases. Chronic respiratory failure was observed in 20% of cases. Factors significantly associated with an unfavorable outcome included hemoptysis (p=0.008), the need for corticosteroid treatment (p=0.009), Acute respiratory failure (p=0.05), and echographic dilation of the right cavities (p=0.002).
conclusionsThe clinical phenotype of sarcoidosis can be extremely diverse.Thoracic computed tomography plays an important role in the diagnosis and monitoring of the disease. The evolution of sarcoidosis is variable and depends on the occurrence of complications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.